Femasys IncFEMY
What Femasys Inc does.
We are a leading biomedical innovator, addressing significant unmet needs in women’s health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company is a U.S. manufacturer that has received global regulatory approvals for its product portfolio, which is currently being commercialized in the U.S. and key international markets. FemaSeed ® Intratubal Insemination, a groundbreaking first-step infertility treatment delivering sperm directly to the site of conception, is U.S. FDA-cleared and approved in Europe, United Kingdom (UK), Canada, Israel, Australia and New Zealand. A peer-reviewed publication of positive data from its pivotal clinical trial of FemaSeed demonstrated effectiveness and safety with high satisfaction from both patients and practitioners. FemSperm ® , which includes setup, preparation and analysis kits designed to expand our infertility portfolio and, for the first time, enables gynecologists to perform in-office sperm preparation and analysis for use with FemaSeed. FemVue ® , a companion diagnostic for fallopian tube assessment via ultrasound, is U.S. FDA-cleared and approved in Europe, UK, Canada, Japan, Israel, Australia and New Zealand. FemVue Controlled is US FDA-cleared diagnostic device and is the next-generation design integrating features of FemVue and FemChec ® technologies into a single platform, enabling multiple clinical uses within one solution, including confirmation of tubal patency prior to use with FemaSeed. FemCerv ® , an endocervical tissue sampler for cervical cancer diagnosis, is U.S. FDA-cleared and approved in Europe, UK, Canada, Israel and New Zealand.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $1.2M | $1.2M | $1.1M | $1.6M | $2.3M |
| Net income | -$6.9M | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
| Free cash flow | -$4.9M | -$8.2M | -$11.1M | -$11.4M | -$20.2M | -$19.2M |
More on FEMY.
- Femasys Inc summary
- Femasys Inc financial statements
- Femasys Inc key metrics
- Femasys Inc health scores and style box
- Femasys Inc earnings
- Femasys Inc dividends
- Femasys Inc valuation
- Femasys Inc ownership and insiders
- Femasys Inc peers
Figures from Femasys Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.